stoxline Quote Chart Rank Option Currency Glossary
Scilex Holding Company (SCLX)
0.8978  -0.002 (-0.24%)    04-19 16:00
Open: 0.9
High: 0.9636
Volume: 2,095,976
Pre. Close: 0.9
Low: 0.8002
Market Cap: 149(M)
Technical analysis
2024-04-19 5:12:11 PM
Short term     
Mid term     
Targets 6-month :  1.58 1-year :  1.98
Resists First :  1.35 Second :  1.7
Pivot price 1.32
Supports First :  0.8 Second :  0.66
MAs MA(5) :  1.08 MA(20) :  1.37
MA(100) :  1.53 MA(250) :  3.09
MACD MACD :  -0.2 Signal :  -0.1
%K %D K(14,3) :  7.4 D(3) :  6.2
RSI RSI(14): 22.1
52-week High :  9.35 Low :  0.8
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ SCLX ] has closed below the lower bollinger band by 0.6%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 17.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.97 - 0.97 0.97 - 0.98
Low: 0.79 - 0.79 0.79 - 0.8
Close: 0.89 - 0.9 0.9 - 0.91
Company Description

Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.

Headline News

Tue, 16 Apr 2024
Scilex to reduce R&D expenses, comments on actions post Change Healthcare cyberattack - Seeking Alpha

Tue, 16 Apr 2024
Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results For Gross and Net Sales for ZTlido ... - GlobeNewswire

Wed, 27 Mar 2024
Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of ... - GlobeNewswire

Mon, 25 Mar 2024
Scilex Holding Ends Equity Purchase Deal with Yorkville - - TipRanks

Fri, 15 Mar 2024
Scilex Holding Company's Wholly Owned Subsidiary, Scilex - GlobeNewswire

Tue, 05 Mar 2024
Scilex Holding Company Announces Closing of $10 Million Bought Deal Offering - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Drug Manufacturers - General
Shares Out 106 (M)
Shares Float 43 (M)
Held by Insiders 37.7 (%)
Held by Institutions 16 (%)
Shares Short 6,580 (K)
Shares Short P.Month 7,240 (K)
Stock Financials
EPS -1.28
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -1.74
Profit Margin -244.7 %
Operating Margin -136.3 %
Return on Assets (ttm) -70.2 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 12.8 %
Gross Profit (p.s.) 0
Sales Per Share 0.44
EBITDA (p.s.) -0.96
Qtrly Earnings Growth 0 %
Operating Cash Flow -21 (M)
Levered Free Cash Flow 34 (M)
Stock Valuations
PE Ratio -0.71
PEG Ratio 0
Price to Book value -0.52
Price to Sales 2.03
Price to Cash Flow -4.61
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android